REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds ...
Machine learning-based survival prediction in spinocerebellar ataxia type 3 (SCA3) using DeepSurv, random survival forest, deep Cox mixtures, and Cox proportional hazards models.
In a press release from February 24th, 2026, Vico Therapeutics have announced that participants are now being dosed in a new fourth arm of their ongoing Phase 1/2a clinical trial of VO659, a drug ...
Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is a severe neurodegenerative disorder exhibiting extensive neuronal death affecting diverse brain regions [1], such ...
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company developing genetic medicines for ultra-rare and rare conditions, today announced that the ...
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the ...
Vico Therapeutics recently presented at several conferences to share an interim update on their Phase 1/2a clinical trial testing their drug called VO659, which targets the repeating C-A-Gs in people ...
Biohaven is on the cusp of a new drug application filing in a rare neurodegenerative disorder that currently has no approved therapies, a surprising development for a molecule with a long list of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results